- Atlas
- Natural Sciences
- Medicinal Chemistry
Medicinal Chemistry
Medicinal chemistry is the branch of chemistry that designs, makes, and studies molecules intended to prevent or treat disease.
11 frameworks, from 1830 to today · Chemistry · Natural Sciences
- Natural Product Isolation and Semisynthesis 1830-Present
- Structure–activity relationship 1890-Present
- Chemotherapy and the Magic Bullet 1909-Present
- Receptor theory 1910-Present
- High-throughput screening 1930-Present
- Mechanism-Based Inhibitor Design 1960-Present
- Computational and In Silico Drug Design 1980-Present
- Structure-Based Drug Design 1980-Present
- Biologic and Macromolecular Therapeutics 1985-Present
- Targeted therapy 1990-Present
- Fragment-based lead discovery 1995-Present
Overview
Medicinal chemistry is the branch of chemistry that designs, makes, and studies molecules intended to prevent or treat disease1. Its practitioners ask a deceptively simple question: how does a chemical structure produce a biological effect, and how can that structure be changed to make the effect stronger, safer, or more selective? What is at stake is the difference between a substance that poisons and one that heals—often a matter of a few atoms. The field sits at the junction of organic synthesis, pharmacology, and biology, and its history is a long movement from trial-and-error toward deliberate design1.
From Galenicals to Pure Compounds
For most of history, medicines were plant and mineral preparations used on the authority of tradition. The iatrochemists of the sixteenth and seventeenth centuries—Paracelsus and his followers—argued that specific chemical substances, not vague humours, acted on specific organs, and they introduced mineral remedies such as mercury and antimony. But the decisive shift came in the early nineteenth century, when chemists learned to isolate the active principle of a crude drug. In 1805 the pharmacist Friedrich Sertürner isolated morphine from opium, and in 1817 identified it as an alkaloid—a nitrogen-containing plant base with basic (alkali-like) properties. Quinine from cinchona bark, strychnine, and caffeine followed23. Isolation turned a variable plant extract into a weighable, testable substance, and it opened the possibility of modifying it.
Semisynthesis and the First Structure–Activity Studies
Once a natural product was in hand, chemists could alter it. In the 1830s and after, derivatives of morphine and quinine were prepared and tested, and by the late nineteenth century a rough empirical rule had emerged: small structural changes could shift potency or toxicity. The most famous early case is acetylsalicylic acid. Salicylic acid, isolated from willow bark, relieved pain and fever but irritated the stomach; in 1897 Felix Hoffmann at Bayer acetylated it to make aspirin, a compound that retained the analgesic effect with less gastric irritation. This is semisynthesis: chemical modification of a natural product to improve it4. The same era saw the systematic study of structure–activity relationships (SAR)—the practice of correlating changes in a molecule's structure with changes in its biological effect5. It was still largely trial and error, but it established that activity is a property of structure, not of a plant.
The Magic Bullet and the Birth of Chemotherapy
The idea that a drug could be aimed at a pathogen and spare the host was articulated by Paul Ehrlich, who called it the Zauberkugel, the magic bullet67. Ehrlich's target was syphilis, caused by the spirochete Treponema pallidum8. Working through hundreds of arsenic compounds, in 1909 he and Sahachiro Hata found that compound 606, arsphenamine (sold as Salvarsan), killed the organism with tolerable toxicity. This was the first synthetic chemotherapeutic agent—a drug made in the laboratory to attack a specific infectious agent98. Ehrlich's reasoning, that a compound could bind selectively to a parasite's receptor, was a direct application of receptor ideas to therapy10.
Receptor Theory and Pharmacodynamics
The notion that drugs act by binding to specific sites on cells was formalized by John Newport Langley and, above all, by Archibald Hill and later Alfred Clark in the early twentieth century. Hill's 1910 analysis of nicotine's action on muscle showed that the response followed a saturable curve, exactly as if the drug were occupying a limited number of sites. Clark's work in the 1920s and 1930s put this on a quantitative footing: the effect of a drug depends on its concentration and on its affinity for a receptor. This is the core of pharmacodynamics—what a drug does to the body1112. The receptor concept gave medicinal chemists a target to design against and a language (affinity, efficacy, dose–response) for comparing compounds.
Industrial Screening and the Antibiotic Era
The mid-twentieth century brought mass screening: testing thousands of compounds or fermentation broths against a biological assay. The discovery of penicillin by Alexander Fleming in 1928, and its development as a drug in the 1940s, showed that microorganisms produce potent antibacterial substances13. The subsequent hunt for antibiotics—streptomycin, tetracycline, and many others—was driven by systematic screening of soil microbes. In parallel, pharmaceutical companies built large libraries of synthetic compounds and screened them for activity. Screening was powerful but blind: it found hits without explaining why they worked, and it consumed enormous effort for each success.
Mechanism-Based Inhibitor Design
A more rational approach grew from understanding how an enzyme works14. Enzymes are proteins that catalyze reactions; many drugs work by blocking a specific enzyme. In the 1960s and 1970s, medicinal chemists began designing inhibitors that mimic the enzyme's natural substrate or its transition state—the fleeting high-energy arrangement during catalysis. A classic case is the design of inhibitors of HMG-CoA reductase, the enzyme that makes cholesterol; the statin drugs, developed from the 1970s, were built on knowledge of the enzyme's substrate. Mechanism-based design meant the chemist could reason from the reaction mechanism to a structure, rather than screening blindly.
Structure-Based Drug Design
When X-ray crystallography began to reveal the three-dimensional structures of proteins, a new route opened: look at the target's binding site and design a molecule to fit it15. This is structure-based drug design15. Early successes came in the 1980s and 1990s, notably the HIV protease inhibitors, where the enzyme's structure guided the placement of chemical groups into its active site. The method requires a structure, a model of how a ligand (a molecule that binds) sits in the pocket, and iterative synthesis and testing15. It made the target itself the blueprint.
Computational and In Silico Design
Computers entered the field alongside structural biology15. Molecular mechanics and quantum-chemical methods could estimate how strongly a candidate would bind, and docking programs could screen virtual libraries by fitting molecules into a protein site1516. Computational (in silico) drug design became a standard preliminary filter, narrowing the enormous space of possible molecules before synthesis. Its predictions are approximate—scoring functions are imperfect—but it changed the economics of discovery by letting chemists test ideas on a screen before making them in the lab15.
Fragment-Based Drug Design
A related strategy emerged in the 1990s and 2000s: instead of starting with a large molecule, start with small fragments that bind weakly, then grow or link them into a potent drug. Fragment-based drug design exploits the fact that weak binding can be detected and measured, and that small fragments sample chemical space efficiently. It has produced clinical candidates, notably in kinase inhibition, and it complements high-throughput screening by finding starting points that larger libraries miss.
Molecular Biology, Targeted Therapy, and Biologics
The rise of molecular biology from the 1950s onward transformed what a drug target could be. Understanding genes, receptors, and signaling pathways allowed "targeted therapy"—drugs aimed at a specific molecular abnormality, such as the BCR-ABL fusion protein in chronic myeloid leukemia, which imatinib (Gleevec) inhibited from 2001. At the same time, the boundary of medicinal chemistry widened to include biologic and macromolecular therapeutics: antibodies, proteins, and nucleic acid drugs17. These are not small molecules, and their design draws on biotechnology and immunology, but they are now a major part of what the field delivers, and medicinal chemists work alongside them on conjugation, formulation, and delivery17.
The Present
Today medicinal chemistry combines all of these strands. Structure-based and fragment-based design, computational screening, mechanism-based inhibitor design, and SAR optimization are used together in iterative cycles, with molecular biology supplying ever more precise targets151819205. The questions still open are familiar in shape: how to predict toxicity and selectivity before the clinic, how to reach targets once thought undruggable, and how to integrate small molecules with biologics. The field's history is a steady replacement of guesswork by understanding—of the molecule, of the target, and of the body that receives both.
References
- Medicinal chemistry, Wikipedia
- Alkaloid (History), Wikipedia
- Quinine, Wikipedia
- Semisynthesis, Wikipedia
- Structure–activity relationship, Wikipedia
- Magic bullet (medicine), Wikipedia
- Paul Ehrlich, Wikipedia
- Arsphenamine (History, introduction), Wikipedia
- Prodrug (History), Wikipedia
- Receptor theory, Wikipedia
- Pharmacology, Wikipedia
- Pharmacodynamics, Wikipedia
- Penicillin, Wikipedia
- Enzyme inhibitor, Wikipedia
- Drug design (Structure-based, Computer-aided drug design), Wikipedia
- Docking (molecular), Wikipedia
- Biopharmaceutical, Wikipedia
- Fragment-based lead discovery, Wikipedia
- Virtual screening, Wikipedia
- Transition state analog, Wikipedia
The frameworks of Medicinal Chemistry
Each framework is a way of working the field has used: when it held, and the question it answers.
- 1830-Present
Natural Product Isolation and Semisynthesis
How can the active principle of a natural substance be isolated and improved?
- 1890-Present
Structure–activity relationship
How does changing a molecule's structure change its biological effect?
- 1909-Present
Chemotherapy and the Magic Bullet
How can a chemical be made to attack a pathogen and spare the host?
- 1910-Present
Receptor theory
How do drugs bind to specific sites and produce a response?
- 1930-Present
High-throughput screening
How can many compounds be tested quickly for biological activity?
- 1960-Present
Mechanism-Based Inhibitor Design
How can knowledge of an enzyme's mechanism guide the design of an inhibitor?
- 1980-Present
Computational and In Silico Drug Design
Can a computer predict which molecules will bind a target?
- 1980-Present
Structure-Based Drug Design
How can the three-dimensional structure of a target guide drug design?
- 1985-Present
Biologic and Macromolecular Therapeutics
How can large biological molecules be used and delivered as drugs?
- 1990-Present
Targeted therapy
How can a drug be aimed at a specific molecular abnormality?
- 1995-Present
Fragment-based lead discovery
How can small weakly binding fragments be grown into potent drugs?
How the ideas connect
Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.
Structure–activity relationship grew out of Natural Product Isolation and Semisynthesis
Once pure natural products such as morphine and quinine could be isolated and chemically modified, chemists began systematically correlating structural changes with changes in biological effect. This practice became the structure–activity relationship tradition in the late nineteenth century.
Carried by Friedrich Sertürner; Felix Hoffmann.
Chemotherapy and the Magic Bullet influenced by Structure–activity relationship
Ehrlich's search for a magic bullet depended on the idea that a compound's structure determines its selective biological action, and he systematically varied arsenic structures to find arsphenamine. The SAR habit of modifying structures to improve selectivity carried directly into chemotherapy.
Carried by Paul Ehrlich; Sahachiro Hata.
Targeted therapy grew out of Chemotherapy and the Magic Bullet
Targeted therapy generalized Ehrlich's magic-bullet aim from pathogens to specific molecular abnormalities in cancer, such as the BCR-ABL fusion protein inhibited by imatinib. The idea of a drug aimed at a defined molecular target carried directly from chemotherapy to targeted oncology.
Carried by Paul Ehrlich.
Mechanism-Based Inhibitor Design reacted against High-throughput screening
Mechanism-based inhibitor design arose as a rational alternative to blind mass screening, which found active compounds without explaining why they worked. Chemists began reasoning from enzyme mechanism to structure instead of relying on screening hits.
Structure-Based Drug Design influenced by Mechanism-Based Inhibitor Design
Structure-based drug design took the mechanism-based aim of fitting an inhibitor to an enzyme's active site and made the three-dimensional structure of that site the explicit blueprint. Early HIV protease inhibitors were designed by placing groups into the crystallographically determined active site.
Fragment-based lead discovery grew out of Structure-Based Drug Design
Fragment-based lead discovery grew out of structure-based design by starting with small weakly binding fragments identified in the target's binding site and then growing or linking them. It used the same structural information but sampled chemical space with smaller pieces.
High-throughput screening influenced by Structure–activity relationship
Mass screening of compound libraries was organized around the expectation, established by SAR work, that structural variation would produce detectable differences in activity. Screening scaled up the empirical comparison of structures that SAR had made routine.
Mechanism-Based Inhibitor Design influenced by Receptor theory
The receptor concept supplied the target-oriented thinking that mechanism-based design extended to enzymes, where the substrate-binding site played the role of the receptor. Designers reasoned about how a molecule occupies a specific protein site.
Targeted therapy influenced by Receptor theory
Targeted therapy depended on the receptor and signaling-pathway concepts that receptor theory had established, aiming drugs at specific receptors or kinases. Molecular biology turned those targets into actionable abnormalities.
Computational and In Silico Drug Design influenced by High-throughput screening
Virtual screening extended the logic of high-throughput screening to computational libraries, testing molecules in silico before synthesis. The goal of filtering enormous numbers of compounds for activity carried over from physical screening.
Fragment-based lead discovery reacted against High-throughput screening
Fragment-based discovery was promoted partly as a complement and corrective to high-throughput screening, finding starting points that large libraries missed by using small fragments that bind weakly. It defined itself against the limitations of screening large molecules.
Fragment-based lead discovery influenced by Computational and In Silico Drug Design
Fragment-based discovery used computational methods to screen and optimize small fragments, drawing on in silico tools developed for virtual screening. Computational scoring helped identify and grow weak-binding fragments.
Beyond the field
Where Medicinal Chemistry's ideas came from in other fields, and what they led to there: the strongest 12 of 82 links.
Structure–activity relationship influenced by Structural theory in Organic Chemistry
Structural theory in organic chemistry, with its valence rules and constitutional formulas, supplied the very notion of a structure whose variation could be related to activity; without it SAR has no variable to vary.
Chemotherapy and the Magic Bullet influenced Secondary Metabolite and Antibiotic Discovery in Mycology
Chemotherapy and the magic bullet supplied the selective-toxicity concept and the screening-for-activity approach that antibiotic discovery adopted. The antibiotic programme is the realisation of Ehrlich's chemotherapy ideal using microbial metabolites.
Carried by Paul Ehrlich.
Chemotherapy and the Magic Bullet influenced Chemotherapy in Medical Oncology
Ehrlich's magic-bullet programme, with Salvarsan and later sulphonamide work, supplied the selective-toxicity concept that anticancer chemotherapy took up with nitrogen mustard and antifolates.
Carried by Paul Ehrlich.
Receptor theory influenced Rational drug design in Drug Discovery
Receptor theory as used in medicinal chemistry is the conceptual basis for designing ligands to fit a characterised receptor.
Receptor theory influenced Rational drug design in Pharmacology
Receptor theory gave rational drug design its founding premise of specific drug–receptor interaction, allowing structures to be designed for a known receptor.
Receptor theory influenced Pharmacodynamics in Clinical Pharmacology
Receptor theory supplied pharmacodynamics with its core model of drug action: drugs act by binding specific receptive substances, as formulated by Langley and Ehrlich and later quantified by Clark. This concept is the backbone of pharmacodynamic reasoning.
Carried by John Newport Langley; Paul Ehrlich; A. J. Clark.
Receptor theory led to Schild equation in Receptor Theory And Signal Transduction
The Schild equation formalised receptor theory for competitive antagonism, deriving the parallel shift of dose–response curves from mass-action occupancy of receptors.
Carried by Heinz Otto Schild.
High-throughput screening influenced High-Throughput Screening and Predictive Toxicology in Environmental Toxicology
Predictive toxicology adopted high-throughput screening: automated multi-well assays developed in medicinal chemistry were repurposed to screen chemicals against toxicity pathways in vitro.
Mechanism-Based Inhibitor Design grew out of Rational drug design in Drug Discovery
Rational drug design, built on knowing the target and designing molecules to fit it, is the parent programme from which mechanism-based inhibitor design grew: the inhibitor is designed around a known enzymatic mechanism rather than a static fit.
Mechanism-Based Inhibitor Design grew out of Rational drug design in Pharmacology
Rational drug design in pharmacology supplied the target-directed, structure-guided approach that mechanism-based inhibitor design refined by adding the reaction mechanism of the enzyme as the design constraint.
Computational and In Silico Drug Design grew out of Rational drug design in Drug Discovery
Computational drug design grew out of rational drug design as its computational branch: the receptor-fitting and physicochemical-property reasoning of rational design was implemented in software for docking, QSAR and de novo design.
Computational and In Silico Drug Design influenced by Computational chemistry in Chemistry
Molecular mechanics, quantum chemistry and quantitative structure-activity methods developed in computational chemistry were taken up by drug designers as the basis for in silico ligand design and property prediction. The later field is unthinkable without these computational methods.

Medicinal Chemistry is a planet in Nousfarer
Its city has a tower for each of these 11 frameworks. Land, walk in, and climb one concept at a time.
Land on Medicinal ChemistryRelated fields
Fields its ideas are linked to
- Drug Discovery 21 links
- Pharmacology 6 links
- Pharmacodynamics 5 links
- Pharmaceutical Chemistry 5 links
- Organic Chemistry 4 links
- Precision Oncology 4 links
- Medical Oncology 3 links
- Pharmaceutics 3 links
- Structural Biology 2 links
- Chemistry 2 links
- Materials Chemistry 2 links
- Psychopharmacology 2 links
More in Chemistry
- Analytical Chemistry
- Catalysis
- Chemical Biology
- Chemical Kinetics
- Chemistry
- Computational Chemistry
- Electrochemistry
- Green Chemistry
- Inorganic Chemistry
- Materials Chemistry
- Nuclear Chemistry
- Organic Chemistry
- Organometallic Chemistry
- Physical Chemistry
- Spectroscopy
- Supramolecular Chemistry
- Surface Chemistry
- Theoretical Chemistry
See where Medicinal Chemistry sits on the Map of Human Knowledge